{{Use dmy dates|date=February 2013}}
{{chembox
| ImageFile=5-Methyltetrahydrofolate.png
| ImageSize=220px
| IUPACName=(2''S'')-2-[ [4-[(2-Amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl) methylamino]benzoyl]amino]pentanedioic acid
| OtherNames=(<small>L</small>-5-Me-THFA, <small>L</small>-5-Me-H<sub>4</sub>FA),<br />anion: <small>L</small>-5-methyltetrahydrofolate (<small>L</small>-5-Me-THF, <small>L</small>-5-Me-H<sub>4</sub>F), <small>L</small>-methylfolate<br>Metafolin 
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 8S95DH25XC

| ChemSpiderID = 392351
| SMILES = CN1c2c([nH]c(nc2=O)N)NC[C@@H]1CNc3ccc(cc3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
| InChI = 1/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12-,13-/m0/s1
| InChIKey = ZNOVTXRBGFNYRX-STQMWFEEBP
| StdInChI = 1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12-,13-/m0/s1
| StdInChIKey = ZNOVTXRBGFNYRX-STQMWFEESA-N
| CASNo=134-35-0
| CASNo1 = 151533-22-1
| CASNo1_Comment = (calcium salt)
| PubChem=444412
| PubChem1 = 15341110
| PubChem1_Comment = (calcium salt)
| KEGG = D09353
| MeSHName=5-methyltetrahydrofolate

}}
|Section2={{Chembox Properties
| C=20 | H=25 | N=7 | O=6
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section7={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
  }}
|Section6={{Chembox Pharmacology
| ATCCode_prefix = B03
| ATCCode_suffix = BB51
| AdminRoutes = oral, transdermal, subcutaneous
| Bioavail =
| Metabolism =
| HalfLife =
| ProteinBound =
| Excretion =
| Legal_status =
| Legal_US = OTC
| Legal_US_comment =
| Legal_UK =
| Legal_AU =
| Legal_CA =
| Pregnancy_category= N{{where|date=April 2015}}
| Pregnancy_AU =
| Pregnancy_US =
 }}
}}

'''Levomefolic acid''' ([[International Nonproprietary Name|INN]]) (also known as '''L-5-MTHF''', '''L-methylfolate''' and '''L-5-methyltetrahydrofolate''' and '''(6''S'')-5-methyltetrahydrofolate''', and '''(6''S'')-5-MTHF''') is the primary biologically active form of folate used at the cellular level for [[DNA]] reproduction, the [[cysteine]] cycle and the regulation of [[homocysteine]]. It is also the form found in circulation and transported across membranes into tissues and across the blood-brain barrier. In the cell, L-methylfolate is used in the [[methylation]] of homocysteine to form [[methionine]] and [[tetrahydrofolate]] (THF). THF is the immediate acceptor of one carbon units for the synthesis of thymidine-DNA, purines (RNA and DNA) and methionine. The un-methylated form, [[folic acid]] (vitamin B<sub>9</sub>), is a synthetic form of folate, and must undergo enzymatic reduction by [[methylenetetrahydrofolate reductase]] (MTHFR) to become biologically active.<ref name="Pietrzik">{{cite journal|last=Pietrzik|first=Klaus |author2=Lynn Bailey |author3=Barry Shane|title=Folic Acid and L-5-Methyltetrahydrofolate Comparison of Clinical Pharmacokinetics and Pharmacodynamics|journal=Clinical Pharmacokinetics|year=2010|pages=535–548|pmid=20608755|doi=10.2165/11532990-000000000-00000|volume=49|issue=8}}</ref>

It is synthesized in the absorptive cells of the small intestine from polyglutamylated dietary folate. It is a methylated derivative of tetrahydrofolate. Levomefolic acid is generated by MTHFR from [[5,10-methylenetetrahydrofolate]] (MTHF) and used to recycle homocysteine back to methionine by [[methionine synthase]] (MS).<ref name=pubchem444412>{{citation|url=https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?q=all&cid=444412#ec|title=5-methyltetrahydrofolate - Compound Summary |work=PubChem|publisher=NCBI|accessdate=2012-09-25}}</ref>

L-methylfolate is water-soluble and primarily excreted via the kidneys. In a study of 21 subjects with coronary artery disease, peak plasma levels were reached in one to three hours following oral or [[parenteral]] administration. Peak concentrations were found to be more than seven times higher than folic acid (129 [[Nanogram|ng]]/ml vs. 14.1&nbsp;ng/ml).<ref>http://intetlab.com/site/products/Cerefolin-NAC_package-insert_%204-26-10.pdf</ref>

Levomefolate calcium, a calcium [[salt (chemistry)|salt]] of levomefolic acid, developed and produced by [[Merck KGaA]], is sold under the brand names '''Metafolin''' (a registered trademark of [[Merck KGaA]]) and incorporated in '''Deplin''' (trademark of [[Pamlab]], LLC).<ref name=eMedTV>{{cite web|last=Lakely|first=Susan|title=RPH|url=http://mental-health.emedtv.com/l-methylfolate/l-methylfolate.html|work=L-Methylfolate|accessdate=12 January 2012}}</ref>

==Metabolism==

[[File:MTHFR metabolism.svg|center|thumb|600px|MTHFR metabolism: folate cycle, methionine cycle, trans-sulfuration and [[hyperhomocysteinemia]]. [[5-MTHF]]: 5-methyltetrahydrofolate; 5,10-methyltetrahydrofolate; [[Bcl-2-associated X protein|BAX]]: Bcl-2-associated X protein; [[BHMT]]: betaine-homocysteine S-methyltransferase; [[cystathionine beta synthase|CBS]]: cystathionine beta synthase; [[cystathionine gamma-lyase|CGL]]: cystathionine gamma-lyase; [[dihydrofolate|DHF]]: dihydrofolate (vitamin B9); [[dimethylglycine|DMG]]: dimethylglycine; [[dTMP]]: thymidine monophosphate; [[dUMP]]: deoxyuridine monophosphate; [[flavin adenine dinucleotide|FAD]]<sup>+</sup> flavine adenine dicucleotide; [[10-formyltetrahydrofolate|FTHF]]: 10-formyltetrahydrofolate; [[methionine synthase|MS]]: methionine synthase; [[MTHFR]]: mehtylenetetrahydrofolate reductase; [[S-adenosyl-L-homocysteine|SAH]]: S-adenosyl-L-homocysteine; [[S-adenosyl-L-methionine|SAME]]: S-adenosyl-L-methionine; [[tetrahydrofolate|THF]]: tetrahydrofolate.]]

==Medical uses==

=== Major depressive disorder ===

Preliminary research suggests that levomefolic acid (L-methylfolate) taken with a [[First line agent|first-line]] [[antidepressant]]<ref>{{Cite journal|last=Sussman|first=Norman|date=March 1, 2009|title=Selecting a First-line Antidepressant: New Analysis|url=http://primarypsychiatry.com/selecting-a-first-line-antidepressant-new-analysis/|journal=Primary Psychiatry|volume=16|pages=19–22|pmid=}}</ref> may provide an [[Adjunctive therapy|adjunctive]] antidepressant effect for individuals who do not respond or have only a partial therapeutic response to [[Selective serotonin reuptake inhibitor|SSRI]] or [[Serotonin–norepinephrine reuptake inhibitor|SNRI]] medication.<ref>{{Cite journal|last=Ginsberg|first=Lawrence|last2=Oubre|first2=Alondra|last3=Daoud|first3=Yahya|date=January 2011|title=L-methylfolate Plus SSRI or SNRI from Treatment Initiation Compared to SSRI or SNRI Monotherapy in a Major Depressive Episode|journal=Innovations in Clinical Neuroscience|volume=8|issue=1|pages=19–28|pmc=3036555|pmid=21311704}}</ref><ref>{{Cite journal|last=Papakostas|first=George I.|last2=Shelton|first2=Richard C.|last3=Zajecka|first3=John M.|last4=Etemad|first4=Bijan|last5=Rickels|first5=Karl|last6=Clain|first6=Alisabet|last7=Baer|first7=Lee|last8=Dalton|first8=Elizabeth D.|last9=Sacco|first9=Garret R.|date=2012-12-01|title=L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials|journal=The American Journal of Psychiatry|volume=169|issue=12|pages=1267–1274|doi=10.1176/appi.ajp.2012.11071114|issn=1535-7228|pmid=23212058}}</ref><ref>{{Cite journal|last=Shelton|first=Richard C.|last2=Sloan Manning|first2=J.|last3=Barrentine|first3=Lori W.|last4=Tipa|first4=Eleanor V.|date=2013|title=Assessing Effects of l-Methylfolate in Depression Management: Results of a Real-World Patient Experience Trial|journal=The Primary Care Companion for CNS Disorders|volume=15|issue=4|doi=10.4088/PCC.13m01520|issn=2155-7772|pmc=3869616|pmid=24392264}}</ref><ref>{{Cite journal|last=Papakostas|first=George I.|last2=Shelton|first2=Richard C.|last3=Zajecka|first3=John M.|last4=Bottiglieri|first4=Teodoro|last5=Roffman|first5=Joshua|last6=Cassiello|first6=Clair|last7=Stahl|first7=Stephen M.|last8=Fava|first8=Maurizio|date=2014-04-15|title=Effect of Adjunctivel-Methylfolate 15 mg Among Inadequate Responders to SSRIs in Depressed Patients Who Were Stratified by Biomarker Levels and Genotype|url=http://www.psychiatrist.com/JCP/article/Pages/2014/v75n08/v75n0813.aspx|journal=The Journal of Clinical Psychiatry|language=English|volume=75|issue=08|pages=855–863|doi=10.4088/jcp.13m08947|issn=0160-6689}}</ref><ref>{{Cite journal|last=Shelton|first=Richard C.|last2=Pencina|first2=Michael J.|last3=Barrentine|first3=Lori W.|last4=Ruiz|first4=Juan A.|last5=Fava|first5=Maurizio|last6=Zajecka|first6=John M.|last7=Papakostas|first7=George I.|date=2015-12-23|title=Association of Obesity and Inflammatory Marker Levels on Treatment Outcome|url=http://www.psychiatrist.com/jcp/article/pages/2015/v76n12/v76n1212.aspx|journal=The Journal of Clinical Psychiatry|language=English|volume=76|issue=12|pages=1635–1641|doi=10.4088/jcp.14m09587|issn=0160-6689}}</ref><ref>{{Cite journal|last=Zajecka|first=John M.|last2=Fava|first2=Maurizio|last3=Shelton|first3=Richard C.|last4=Barrentine|first4=Lori W.|last5=Young|first5=Page|last6=Papakostas|first6=George I.|date=2016-05-25|title=Long-Term Efficacy, Safety, and Tolerability of <span style="font-variant:small-caps; "> l</span>-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors|url=http://www.psychiatrist.com/jcp/article/pages/2016/v77n05/v77n0521.aspx|journal=The Journal of Clinical Psychiatry|language=English|volume=77|issue=5|pages=654–660|doi=10.4088/jcp.15m10181|issn=0160-6689}}</ref>

=== Cardiovascular disease and cancer ===

Levomefolic acid (and folic acid in turn) has been proposed for treatment of cardiovascular disease<ref>{{Cite journal|last=Willems|first=Frank F|date=March 2004|title=Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease|journal=Br J Pharmacol|publisher=Nature Publishing Group|volume=141|issue=5|pages=825–830|doi=10.1038/sj.bjp.0705446|pmc=1574248|pmid=14769778|author2=Boers GHJ|author3=Blom HJ|author4=Aengevaeren WRM|author5=Verheugt FWA}}</ref><ref>{{Cite journal|last=Iris P Fohr, Reinhild Prinz-Langenohl, Anja Brönstrup, Anja M Bohlmann, Heinz Nau, Heiner K Berthold, and Klaus Pietrzik|last2=Prinz-Langenohl|first2=R|last3=Brönstrup|first3=A|last4=Bohlmann|first4=AM|last5=Nau|first5=H|last6=Berthold|first6=HK|last7=Pietrzik|first7=K|year=2002|title=5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women|url=http://webcache.googleusercontent.com/search?q=cache:NriMrILGOoIJ:www.geno-type.com/ts/GenoType/pdf/Fohr.pdf&cd=6&hl=en&ct=clnk|journal=Am J Clin Nutr|publisher=American Society for Clinical Nutrition|volume=75|issue=2|pages=275–282|pmid=11815318|first1=IP|accessdate=}}</ref> and advanced cancers such as breast and [[colorectal cancer]]s.<ref name="StröhleWolters2005">{{cite journal|last2=Wolters|first2=Maike|last3=Hahn|first3=Andreas|year=2005|title=Folic acid and colorectal cancer prevention: Molecular mechanisms and epidemiological evidence (Review)|journal=International Journal of Oncology|doi=10.3892/ijo.26.6.1449|issn=1019-6439|last1=Ströhle|first1=Alexander}}</ref> It bypasses several metabolic steps in the body and better binds [[thymidylate synthase]] with FdUMP, a metabolite of the drug [[fluorouracil]].

==Patent issues==
In March 2012, [[Merck KGaA|Merck & Cie]] of [[Switzerland]], [[Pamlab]] LLC (maker of [[Metanx]] and [[Cerefolin]], Neevo
DHA, and Deplin), and South Alabama Medical Science Foundation (SAMSF) (the plaintiffs) filed a complaint in the [[United States District Court for the Eastern District of Texas]] against four defendants - Macoven Pharmaceuticals (owned by Pernix Therapeutics), Gnosis SpA of Italy, Gnosis U.S.A and Gnosis Bioresearch Switzerland. The plaintiffs alleged that the defendants infringed on several of the plaintiffs' patents.<ref name=6patents>The six patents named were {{patent|US|5997915}}, {{patent|US|6011040}}, {{patent|US|6254904}}, {{patent|US|6673381}}, {{patent|US|7674490}} and {{patent|US|7172778}}.</ref> The Macoven products named in the suit are: "Vitaciric-B", "ALZ-NAC", "PNV DHA", and l-methylfolate calcium (levomefolate calcium).<ref>{{cite news|title=Pernix Therapeutics’ Subsidiary Macoven Pharmaceuticals, LLC Named in Suit by Merck, Pamlab, L.L.C. and Others for Alleged|url=https://www.bloomberg.com/apps/news?pid=conewsstory&tkr=MKGAF:US&sid=aVfdD6EGy6Nc|accessdate=1 October 2012|newspaper=Bloomberg|date=6 March 2012}}</ref>

In September 2012, the same three plaintiffs filed a complaint requesting that the [[United States International Trade Commission|International Trade Commission]] begin an {{uscsub|19|1337|}} investigation of the same four defendants. The complaint states that Gnosis' "Extrafolic-S" and products which are made from it, infringe upon three of their patents: {{patent|US|5997915}}, {{patent|US|6673381}}, and {{patent|US|7172778}}.<ref name=gnosis337>{{cite web|last=Schweibenz |first=Eric W. |title=SAMSF, Merck, and Pamlab File New 337 Complaint Regarding Certain Reduced Folate Nutraceutical Products and L-methylfolate Raw Ingredients Used Therein |url=http://www.oblon.com/samsf-merck-and-pamlab-file-new-337-complaint-regarding-certain-reduced-folate-nutraceutical-product |work=Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P. |archiveurl=https://www.webcitation.org/6B5SUao9V?url=http://www.oblon.com/samsf-merck-and-pamlab-file-new-337-complaint-regarding-certain-reduced-folate-nutraceutical-product |archivedate= 1 October 2012 |date=2012-09-10 |deadurl=yes |df= }}</ref>

==See also==
* [[5,10-Methylenetetrahydrofolate]] (5,10-CH<sub>2</sub>-THF, MTHF)
* [[Methionine synthase]] (MS)
* [[Methylenetetrahydrofolate reductase]] (MTHFR)
* [[S-Adenosylmethionine]] (SAMe)

==References==
<references />

==External links==
*[http://www.fao.org/docrep/008/a0044e/a0044e05.htm#bm5.3 CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca)]
*{{cite journal |pmid=16933051|year=2006|author1=Brockton|first1=N. T.|title=Localized depletion: The key to colorectal cancer risk mediated by MTHFR genotype and folate?|journal=Cancer Causes & Control|volume=17|issue=8|pages=1005–16|doi=10.1007/s10552-006-0051-5}}
*{{cite journal |last=Stahl |first=SM |date=October 2007 |title=Novel Therapeutics for Depression: L-methylfolate as a Trimonoamine Modulator and Antidepressant-Augmenting Agent |journal=CNS Spectrums |volume=12 |issue=10 |pages=739–744 |url=http://www.cnsspectrums.com/aspx/article_pf.aspx?articleid=1267 |pmid=17934378}}

{{Vitamin}}

{{DEFAULTSORT:Methyltetrahydrofolate, 5-}}
[[Category:Folates]]
[[Category:Coenzymes]]
[[Category:Medical food]]
[[Category:Patent case law]]